Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL963061 | 0.99 | KMT2A (0.41) | MEN1KMT2ATSHRLMNACCR5 | |
| SCHEMBL962485 | 0.90 | HSD11B1 (0.51) | MEN1KMT2ATSHRLMNAALDH1A1 | |
| SCHEMBL962557 | 0.90 | ALDH1A1 (0.48) | MEN1KMT2ATSHRLMNAALDH1A1 | |
| SCHEMBL962486 | 0.90 | HSD11B1 (0.51) | MEN1KMT2ATSHRLMNAALDH1A1 | |
| SCHEMBL965719 | 0.82 | LMNA (0.43) | MEN1KMT2ALMNACCR5NPC1 | |
| SCHEMBL17044870 | 0.81 | CTSD (0.42) | MEN1KMT2ALMNACCR5NPC1 | |
| SCHEMBL17044862 | 0.74 | CTSD (0.43) | MEN1KMT2ALMNACCR5NPC1 | |
| SCHEMBL17044842 | 0.74 | CTSD (0.36) | MEN1KMT2ALMNACCR5NPC1 | |
| SCHEMBL17044841 | 0.74 | CTSD (0.36) | MEN1KMT2ALMNACCR5NPC1 | |
| SCHEMBL962195 | 0.71 | HPGD (0.32) | MEN1KMT2ALMNAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | MAVS, IRF3, LSS | MEN1 3268/4885KMT2A 4391/4885TSHR 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.